Overview of the randomized phase III trials in non-small cell lung cancer in North America.

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cause of deaths due to cancer in the United States. Although surgery can be curative for the small group of patients with early stage disease, the majority of patients present with advanced disease, for which treatment is ineffective, resulting in a 5-year overall survival rate of only 13%. Research to discover and evaluate new treatment strategies that will result in a meaningful survival benefit for patients with lung cancer is constantly ongoing. However, the process is cumbersome and requires stringent evaluation of the candidate treatment during each phase of testing. The final step in this long process is to validate the benefit of a new treatment by comparing it with the current standard treatment in the setting of a randomized phase III clinical trial. The new promising treatments for non-small cell lung cancer that are currently in phase III testing in North America are reviewed, and upcoming phase III trials are discussed.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number3 Suppl 8
StatePublished - Jun 1997
Externally publishedYes

Fingerprint

North America
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Therapeutics
Phase III Clinical Trials
Cause of Death
Survival Rate
Randomized Controlled Trials
Survival
Research
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Overview of the randomized phase III trials in non-small cell lung cancer in North America. / Kelly, Karen.

In: Seminars in Oncology, Vol. 24, No. 3 Suppl 8, 06.1997.

Research output: Contribution to journalArticle

@article{3495e54b0714479f8accaea8df2bc883,
title = "Overview of the randomized phase III trials in non-small cell lung cancer in North America.",
abstract = "Lung cancer is the leading cause of deaths due to cancer in the United States. Although surgery can be curative for the small group of patients with early stage disease, the majority of patients present with advanced disease, for which treatment is ineffective, resulting in a 5-year overall survival rate of only 13{\%}. Research to discover and evaluate new treatment strategies that will result in a meaningful survival benefit for patients with lung cancer is constantly ongoing. However, the process is cumbersome and requires stringent evaluation of the candidate treatment during each phase of testing. The final step in this long process is to validate the benefit of a new treatment by comparing it with the current standard treatment in the setting of a randomized phase III clinical trial. The new promising treatments for non-small cell lung cancer that are currently in phase III testing in North America are reviewed, and upcoming phase III trials are discussed.",
author = "Karen Kelly",
year = "1997",
month = "6",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 Suppl 8",

}

TY - JOUR

T1 - Overview of the randomized phase III trials in non-small cell lung cancer in North America.

AU - Kelly, Karen

PY - 1997/6

Y1 - 1997/6

N2 - Lung cancer is the leading cause of deaths due to cancer in the United States. Although surgery can be curative for the small group of patients with early stage disease, the majority of patients present with advanced disease, for which treatment is ineffective, resulting in a 5-year overall survival rate of only 13%. Research to discover and evaluate new treatment strategies that will result in a meaningful survival benefit for patients with lung cancer is constantly ongoing. However, the process is cumbersome and requires stringent evaluation of the candidate treatment during each phase of testing. The final step in this long process is to validate the benefit of a new treatment by comparing it with the current standard treatment in the setting of a randomized phase III clinical trial. The new promising treatments for non-small cell lung cancer that are currently in phase III testing in North America are reviewed, and upcoming phase III trials are discussed.

AB - Lung cancer is the leading cause of deaths due to cancer in the United States. Although surgery can be curative for the small group of patients with early stage disease, the majority of patients present with advanced disease, for which treatment is ineffective, resulting in a 5-year overall survival rate of only 13%. Research to discover and evaluate new treatment strategies that will result in a meaningful survival benefit for patients with lung cancer is constantly ongoing. However, the process is cumbersome and requires stringent evaluation of the candidate treatment during each phase of testing. The final step in this long process is to validate the benefit of a new treatment by comparing it with the current standard treatment in the setting of a randomized phase III clinical trial. The new promising treatments for non-small cell lung cancer that are currently in phase III testing in North America are reviewed, and upcoming phase III trials are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0031156053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031156053&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 Suppl 8

ER -